Evidence map›Paper›PMID 31650038›Full record

ArticleBiochemistry and biophysics reports2019

Differential modulation of transendothelial electrical resistance by TRPV4 agonists is mediated by apoptosis and/or necrosis.

N Pairet, S Mang, T Kiechle, N Laufhäger, P Dietl, D J Lamb

Open access · goldAbstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. The role of TRPV4 in programmed cell deaths.Molecular biology reports · 2024
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

N PairetInstitute of General Physiology, University of Ulm, Ulm, Germany.
S MangImmunology & Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, D-88397, Biberach an der Riß, Germany.
T KiechleImmunology & Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, D-88397, Biberach an der Riß, Germany.
N LaufhägerImmunology & Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, D-88397, Biberach an der Riß, Germany.
P DietlInstitute of General Physiology, University of Ulm, Ulm, Germany.
D J LambImmunology & Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, D-88397, Biberach an der Riß, Germany.
Boehringer Ingelheim (Germany) · DEUniversität Ulm · DEMedizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transient receptor potential vanilloid 4 (TRPV4) has been implicated in many disease conditions also in the lung. Its activation leads to an increase endothelial permeability in an intracellular calcium-influx dependent manner. We investigated its function

Identifiers

PMID31650038
PMCPMC6804647
OpenAlexW2973676222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.